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NON-INVASIVE IMAGING
Non-invasive evaluation of
myocardial fibrosis: implications for
the clinician
Darryl P Leong,1,2 Per Lav Madsen,1 Joseph B Selvanayagam1
The presence and extent of myocardial ﬁbrosis are
key determinants of response to treatment and
prognosis in a number of cardiac conditions. Until
recently, myocardial ﬁbrosis could only be detected
ante mortem by endomyocardial biopsy, which is
associated with procedural risk and sampling error.
The development of novel cardiac imaging tech-
niques and serum assays now permits the accurate
detection and quantiﬁcation of myocardial ﬁbrosis.
These have yielded new insights into disease prog-
nosis and response to treatment.
PATHOGENESIS OF MYOCARDIAL FIBROSIS
Myocardial ﬁbrosis develops in response to a cardiac
insult, which may include ischaemia, pressure or
volume overload, viral infection, or genetically
mediated injury as in hypertrophic cardiomyo-
pathy. Net collagen deposition results from an
imbalance of its synthesis relative to degradation. A
number of enzymes have been identiﬁed as poten-
tial mediators of myocardial extracellular matrix
turnover. The matrix metalloproteinases (MMPs)
are a family of at least 20 calcium dependent
endopeptidases that digest interstitial constituents.
The various MMPs have different substratesd
MMP-1 and -13 are collagenases and MMP-2 and -9
gelatinases. Left ventricular (LV) myocardial MMP
activity in idiopathic dilated cardiomyopathy and
ischaemic cardiomyopathy has been shown to be
greater than in normal hearts.1 Abolition of MMP-9
synthesis has been associated with reduced
myocardial ﬁbrosis and improved LV function in
a rodent model of pressure overload.w1 The tissue
inhibitors of matrix metalloproteinase (TIMPs) are
a family of four proteins that bind to and inhibit the
effects of MMPs (ﬁgure 1). TIMP-1 expression is
reduced in explanted hearts from patients with both
ischaemic and non-ischaemic cardiomyopathy.w2
Regardless of the aetiology and/or molecular
cascade resulting in collagen deposition, the pres-
ence of myocardial ﬁbrosis has both mechanical
effects on cardiac function, mediated by increased
myocardial stiffness, and electrophysiological
effects, by acting as substrate for re-entry and
arrhythmia.
CARDIAC MAGNETIC RESONANCE (CMR)
IMAGING
CMR imaging is established as a major technique
in clinical cardiology and cardiovascular research.
Allied to its well recognised role in accurate and
reproducible measurement of LV volumes and
mass, CMR offers an unprecedented ability to
detect and quantify myocardial ﬁbrosis. It provides
exquisite three dimensional images allowing
concurrent assessment of myocardial structure,
function, and tissue characterisation.
Late gadolinium enhancement (LGE) technique
Gadolinium-DTPA (Gd-DTPA) is a paramagnetic
contrast agent that is used to delineate areas of
injured myocardium. Gd-DTPA reduces hydrogene
proton T1 relaxation times in proportion to its local
concentration. In T1 weighted imaging, tissues
with a shorter T1 relaxation time exhibit greater
signal intensity than those with longer T1 relaxa-
tion times. Gd-DTPA equilibrates rapidly between
intravascular and interstitial spaces, but is excluded
from the intracellular compartment by the intact
cell membrane.w3 Following intravenous adminis-
tration, altered wash-in/wash-out kinetics and an
increased volume of distribution in damaged tissue
(owing to interstitial oedema and/or loss of cell
membrane integrity) account for its pattern of
appearance in these regions.2 Late or ‘delayed’
imaging (after at least 5 min post-contrast) with T1
weighted inversion recovery sequences identiﬁes
conditions associated with expansion of the
extracellular space and hence also with ﬁbrosis.
Ischaemic heart disease
In the clinical realm, contractile abnormalities in
patients with ischaemic heart disease may occur as
a consequence of stunning, hibernation and scar,
with the relative importance of these factors
varying both between and within myocardial
segments and dynamically over time. Detecting
dysfunctional and scarred myocardium (ﬁgure 2) as
opposed to dysfunctional but viable myocardium
is of scientiﬁc and clinical signiﬁcance and there is
now a reasonable body of non-randomised evidence
supporting revascularisation of hibernating
myocardium.w4
In the setting of chronic ischaemic cardiomyo-
pathy, to date there have been two single centre
clinical studies examining the utility of the trans-
mural extent of LGE in predicting recovery
of contractile function. The ﬁrst was performed
by Kim et al in a cohort of 41 patients under-
going revascularisation by either percutaneous
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transluminal coronary angioplasty or coronary
artery bypass grafting. They found that the likeli-
hood of improvement in regional function after
revascularisation decreased progressively as the
transmural extent of LGE before revascularisation
increased.3 This was subsequently conﬁrmed in
a study by Selvanayagam et al, which exclusively
examined patients after surgical revascularisation.4
The ability of LGE-CMR to evaluate those
segments that have severe dysfunction (and often
the most difﬁcult to evaluate with other imaging
techniques) with high diagnostic accuracy is one of
the strengths of the LGE-CMR technique. In addi-
tion, with excellent spatial resolution and contrast
noise ratio, LGE-CMR has high sensitivity to detect
viable myocardium and thus may provide more
sensitive (albeit less speciﬁc) prediction of recovery
of segmental function than inotropic contractile
reserve.
The analysis of what constitutes LGE positivity
in human CMR studies of ischaemic cardiomyo-
pathy has been controversial. In earlier animal model
studies performed by Kim et al, a signal intensity
cut-off 2SD above normal myocardium identiﬁed
accurately the extent of myocardial infarction.w5 A
recent elegant study by Amado et al in a canine
model of myocardial infarction demonstrated that
the full width at half-maximum technique for
quantiﬁcation of volume of myocardial enhance-
ment was the most accurate.w6 This method
requires selection of a seed point within hyper-
enhanced myocardium. Software then identiﬁes all
pixels with signal intensity >50% of this point.
The maximal signal intensity within this region is
determined, and the ﬁnal scar extent is deﬁned as
tissue exhibiting signal intensity >50% that of the
maximal signal intensity. Quantifying scar size by
tissue with signal intensity 2SD above normal
myocardium, as originally described by Kim et al,
was found to overestimate infarct size, whereas ﬁve
and six SD thresholds were closer to histopathology.
Myocardial infarct size as quantiﬁed by the late
gadolinium technique has been demonstrated to be
a powerful predictor of mortality and adverse LV
remodellingdmore powerful than left ventricular
ejection fraction (LVEF).w7 w8 Scar burden as
quantiﬁed by CMR, or indeed single photon emis-
sions computed tomography (SPECT) imaging, has
been shown to be a powerful predictor of response
to cardiac resynchronisation therapy in ischaemic
cardiomyopathy patients.5 w9
Kwong et al reported a high prevalence of
myocardial ﬁbrosis among diabetic patients with
clinical features suspicious of coronary heart
disease, but no history of, or ECG ﬁndings consis-
tent with, prior myocardial infarction.6 The pres-
ence of LGE on CMR was associated with a high
risk of future adverse cardiac events, whereas its
absence portended a favourable 2 year outlook.
Non-ischaemic dilated cardiomyopathy
Autopsy studies suggest that interstitial or
replacement ﬁbrosis is found in at least 57% of
cases of non-ischaemic dilated cardiomyopathy
(NICM) and that up to 20% of the LV myocardial
mass may be scar in these cases.w10 McCrohon et al
reported the CMR ﬁndings of 90 patients with
systolic LV dysfunction, all of whom underwent
coronary angiography.7 They observed 100% prev-
alence of LGE in either a subendocardial or trans-
mural distribution among those with signiﬁcant
coronary disease. In contrast, LGE was absent in
59% of those with NICM, had a patchy, mid-wall
distribution in 28% of cases (ﬁgure 3), and
displayed a subendocardial pattern indistinguish-
able from ischaemic cardiomyopathy in the
Figure 1 Enzymatic cascade resulting in collagen synthesis and degradation.
MMP, matrix metalloproteinase; PICP, carboxy-terminal propeptide of procollagen type I;
PINP, amino-terminal propeptide of procollagen type I; TIMP, tissue inhibitor of matrix
metalloproteinase. The dashed line represents inhibition.
Figure 2 Horizontal long axis late gadolinium cardiac
magnetic resonance image demonstrating hyperenhance-
ment (arrow) typical of scar following myocardial
infarction. The pattern of enhancement ranges from
subendocardial to transmural, and is limited to an arterial
territory.
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remaining 13%. The authors suggested that LGE-
CMR might be an acceptable alternative to coro-
nary angiography in determining the aetiology of
severe cardiomyopathy because of its non-invasive
nature, and because the absence of luminal coro-
nary abnormalities on angiography does not
exclude an ischaemic cause of LV dysfunction. They
postulate that some of those cases without severe
coronary disease may represent re-canalised
myocardial infarction.
Assomull et al found mid-wall LGE in 35% of
patients with established NICM recruited from
a large tertiary hospital setting.8 They reported that
ﬁbrosis extent (using a 2SD signal intensity
threshold) was a signiﬁcant predictor of the devel-
opment of death or hospitalisation, and was supe-
rior to LV volumes and ejection fraction. More
recently, Wu et al reported that among 65 patients
with NICM diagnosed a median of 4 years before,
42% exhibited LGE, involving on average 10% of
myocardial mass. In contrast to the earlier study,
‘ﬁbrosis’ was deﬁned as signal intensity greater than
the peak signal intensity of a remote normal region
of myocardium.w11 The presence of LGE on CMR
was independently associated with a higher risk of
the composite primary outcome of cardiac
mortality, appropriate implantable cardioverter
deﬁbrillator discharge, and hospitalisation for heart
failure.w11 Both these studies were performed in
large tertiary referral centres with patients evalu-
ated often after years of treatment. It is unknown if
the prevalence and extent of LGE detected
myocardial ﬁbrosis is similar in an ambulatory
population of patients with NICM and, further-
more, if this is detected at ﬁrst clinical presentation.
Lastly, it is unclear if the presence of myocardial
ﬁbrosis on LGE-CMR and/or its quantity inﬂuences
the clinical response to medical and cardiac
resynchronisation therapy in NICM.
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a genetic
disorder characterised by the development of
cardiac muscle ﬁbre disarray, dysplasia of small
intramural coronary arterioles, and myocardial
ﬁbrosis. It must be distinguished from hypertensive
LV hypertrophy and athlete’s heart, particularly in
its early stages. Moon et al reported the ability of
LGE-CMR to accurately identify and quantify
replacement ﬁbrosis in HCM.w12 A cross-sectional
study of 21 HCM patients demonstrated ﬁbrosis by
the LGE technique in 81% of cases.9 Scarring was
patchy but occurred predominantly within hyper-
trophied segments (typically observed at the junc-
tion of the right ventricle and interventricular
septum) (ﬁgure 4). Findings from another series
corroborate this pattern of LGE in HCM.10 The
presence of LGE has been shown to be associated
with the incidence of ventricular tachycardia in
HCM patients.11
Valvular heart disease
Chronic valvular heart disease may impose either
a volume load (in the case of mitral or aortic
incompetence) or pressure load (in the case of
aortic stenosis) on the left ventricle. These two
Figure 3 Short axis late gadolinium cardiac magnetic
resonance image demonstrating hyperenhancement
typical of fibrosis in a patient with non-ischaemic dilated
cardiomyopathy (arrow). Fibrosis may be seen mid-wall.
Figure 4 (A) Short axis late gadolinium cardiac
magnetic resonance (CMR) image demonstrating hyper-
enhancement typical of fibrosis in a patient with
hypertrophic cardiomyopathy (arrow). Fibrosis is typically
seen within hypertrophied segments, particularly at the
junction of the right ventricle with the interventricular
septum. (B) Corresponding short-axis cine CMR image of
the left ventricle.
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pathophysiological processes result in different
patterns of chamber remodelling: volume overload
results in eccentric remodelling, in which wall
thickness is reduced relative to chamber volume;
pressure overload causes concentric remodelling,
where wall thickness is maintained or increased
relative to chamber size. Myocardial ﬁbrosis is
a feature of longstanding valvular heart disease
irrespective of the mechanism. CMR has demon-
strated sensitivity of 74% and speciﬁcity of 81% for
detection of myocardial ﬁbrosis in patients with
severe aortic valve disease.w13 Fibrosis quantity was
associated negatively with LVEF. Rudolph et al
reported a 62% prevalence of LGE in patients with
aortic stenosis and LV hypertrophy.10 Weidemann
et al conﬁrmed that myocardial ﬁbrosis is common
in patients with severe, symptomatic aortic
stenosis, and could be detected accurately by
CMR.12 Not surprisingly, they found that
myocardial ﬁbrosis was not reversible following
aortic valve replacement.
Other conditions
Myocardial ﬁbrosis may also be seen in a number of
other cardiac conditions, such as sarcoidosis and
arrhythmogenic right ventricular cardiomyopathy.
The ability of CMR to identify ﬁbrofatty replace-
ment and/or inﬁltration, as well as to provide
images of high spatial resolution in any plane,
permit it a role in their diagnosis.
T1 mapping
The major limitation of late gadolinium enhance-
ment CMR in the detection of myocardial ﬁbrosis
is its reliance on differences in signal intensity
between scarred regions and adjacent normal
myocardium. It thus has reduced sensitivity for the
detection of diffuse myocardial ﬁbrosis, which is
the pathological hallmark of NICM and volume
overloaded conditions. T1 mapping, the calculation
of a post-contrast myocardial T1 time by imaging
a given plane with sequentially increasing inversion
times, has been validated in animal studies as
showing a good correlation with ex vivo ﬁbrosis
content. Reproducibility has been deﬁned, and
more recently this technique has been able to
discriminate heart failure patients from healthy
controls even after excluding myocardial segments
displaying late gadolinium enhancement.13 In this
study, Iles et al performed CMR on 25 patients
with heterogeneous causes of heart failure, and 20
healthy controls. The mid-chamber short axis slice
was imaged at a range of inversion times 15 min
following the administration of 0.2 mmol/kg
gadolinium-DTPA. The average T1 in regions of
interest was measured using specialised software
(ﬁgure 5). They found a signiﬁcant difference in T1
time between LGE positive and negative myocar-
dium among heart failure patients (330630 ms vs
429622 ms, respectively, p¼0.02) and a signiﬁcant
difference in T1 time between the LGE negative
myocardium of heart failure patients and healthy
controls (429622 ms vs 564623 ms, respectively,
p<0.001). Although more work needs to be done on
the robustness of the technique, especially with
respect to multicentre, multi-vendor application,
this technique shows promise in the quantitative
evaluation of diffuse myocardial ﬁbrosis, and hence
may have a potentially wide array of applications
in heart failure, cardiomyopathy, and valvular heart
disease.
ECHOCARDIOGRAPHY
Myocardial composition inﬂuences its acoustic
properties. Collagen is an important cause of ultra-
sound scattering and attenuation. The measure-
ment of peak integrated backscatter and cyclic
variation in integrated backscatter may thus reﬂect
a degree of myocardial ﬁbrosis (ﬁgure 6). Hoyt et al
demonstrated a linear relationship between
myocardial hydroxyproline content as a marker of
ﬁbrosis and magnitude of echocardiographic inte-
grated backscatter in autopsy specimens from
victims of myocardial infarction.w14 Among
a cohort of hypertensive patients, integrated back-
scatter decreased and cyclic variation in integrated
backscatter increased following treatment with
blood pressure lowering agents.14 Myocardial scar,
as deﬁned by two dimensional echocardiographic
wall thickness <6 mm, was associated with
increased acoustic reﬂectance, and predicted
response to cardiac resynchronisation therapy
among patients with ischaemic cardiomyopathy.w15
This technique has a limited role in the assessment
of ﬁbrosis in non-ischaemic cardiomyopathies.
Myocardial strain refers to its degree of defor-
mation through the cardiac cycle. Strain may be
measured by either tissue Doppler imaging or
speckle tracking. The latter technique relies upon
echocardiographic software recognition of myocar-
dial points by their acoustic characteristics, and
measurement of their displacement over the cardiac
cycle (ﬁgure 7). Given the effect of collagen depo-
sition on myocardial deformation, strain measure-
ment may be well suited to indirect evaluation of
myocardial ﬁbrosis. Gjesdal et al and Roes et al have
both demonstrated a high sensitivity and speciﬁcity
for longitudinal strain scores to predict extent of
myocardial scar among patients with ischaemic LV
dysfunction as compared with contrast enhanced
CMR.15 16 Weidemann et al quantiﬁed myocardial
ﬁbrosis histologically in biopsies from the LV
outﬂow tract in 58 aortic valve prosthesis recipients
for severe, symptomatic aortic stenosis.12 Patients
underwent comprehensive echocardiographic eval-
uation (including radial and longitudinal strain and
strain rate imaging using tissue Doppler) preoper-
atively and 9 months postoperatively. The authors
demonstrated uniform improvement in these
parameters only among subjects with no or mild
ﬁbrosis. Baseline radial LV function and LVEF were
similar irrespective of myocardial ﬁbrosis burden,
whereas longitudinal indices of LV function were
signiﬁcantly reduced in those with more extensive
ﬁbrosis. This study suggests that quantitative
evaluation of longitudinal LV function may be
a sensitive tool for detection of the mechanical
effects of myocardial ﬁbrosis.
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NUCLEAR IMAGING
Cardiac nuclear imaging encompasses the tech-
niques of positron emission tomography (PET) and
SPECT, and with these techniques there is now
a wealth of evidence in the assessment of myocar-
dial viability and therefore indirectly of scarred and
ﬁbrotic myocardium. The basic principles of PET
are similar to those of SPECT (both form images by
way of intravenous radioisotopes concentrating in
viable myocardium, giving off g-radiation which is
detected by an external g-camera); however, for
scar detection, PET systems are generally more
sensitive than SPECT systems, having better
spatial resolution, and providing more accurate
attenuation correction.
In patients with ischaemic cardiomyopathy, scar
tissue as detected by PET is a good predictor of lack
of recovery of LV systolic function after coronary
artery bypass surgery, though precise individual
prognostication is difﬁcult.16 17 Also, as expected,
PET provides information on outcome. In a meta-
analysis of 10 such studies (1046 patients),
annualised mortality rates were 4% for those with
viable myocardium who underwent revascularisa-
tion versus 17% for those with viability who did
not.w17 If no viability was demonstrated with PET,
revascularisation was not associated with changes
in mortality rates (annual mortality rates of
6e8%). Such evidence has encouraged studies in
which treatment is based on PET ﬁndings, but so
far the studies have only been partly successful. In
the PARR-2 trial, treatment based on 18F-FDG PET
ﬁndings was equivalent to standard care after
1 year of follow-up.18 In a post-hoc analysis of the
PARR-2 trial data, however, the patients with
ischaemic cardiomyopathy with larger amounts of
perfusionemetabolism mismatch (>7%) did have
improved outcome with revascularisation,w18 and
PET may ﬁnd a place to assess outcome in patients
with critical ischaemic cardiomyopathy in whom
surgery is of risk.
The water perfusable tissue index has emerged as
a candidate for in vivo detection of myocardial
ﬁbrosis by PET.w19 Brieﬂy, the ratio of the water
perfusable tissue fraction to the anatomic tissue
fraction is determined using the tracers H215O and
C15O. In normal individuals, the perfusable tissue
index should be 1.0, but ﬁbrotic tissue is unable to
exchange water rapidly and hence the tissue index
decreases in ﬁbrotic myocardium. In dogs a reduc-
tion of the perfusable tissue index correlates well
with the extent of ﬁbrosis after infarction. In
humans, comparisons have been made to LGE-
CMR in different patient populations. In patients
Figure 5 T1 mapping. (A) Regions of interest are drawn around the left ventricular myocardium at different inversion times. (B) Signal intensities for
each region of interest are fitted to an exponential recovery curve to obtain the myocardial T1 time. Reproduced with permission from Iles et al.13
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with scarring due to myocardial infarction, late
gadolinium enhancement was indeed negatively
correlated (r¼0.65) with the perfusable tissue
index,w20 but the water perfusable tissue index
systematically underestimates the amount of scar
tissue if the latter becomes extensive.w21 With
respect to replacement ﬁbrosis in patients with
HCM where Gd late enhancement was seen, the
perfusable tissue index was essentially unaffected.
The perfusable tissue index was slightly lowered in
the LV free wall of patients with HCM, but not at
all in the septum where myocardial disarray,
oedema, and later ﬁbrosis predominantly takes
place (ﬁgure 8). The authors suggest that hyper-
enhancement by LGE-CMR may not be solely
governed by ﬁbrosis but also (especially so early in
the natural history of HCM) by oedema; however,
in light of missing histology, the ﬁnding may
equally well be attributed to a lack of sensitivity by
the perfusable tissue index technique.
In clinical practice, SPECT is still the more robust
and more often applied technique and a wealth of
evidence testiﬁes to its ability to demonstrate
(larger) viability defects and provide for important
prognostic information. In comparison with PET,
SPECT has more limited spatial resolution. In
Figure 6 Segmental curves representing regional integrated backscatter in the parasternal short axis view by speckle
tracking echocardiography.
Figure 7 Segmental curves representing regional longitudinal left ventricular strain in the apical four chamber view as
determined by speckle tracking echocardiography.
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a study by Wagner et al19 that compared LGE-CMR
with SPECT in a canine model of myocardial injury,
CMR identiﬁed 92% of all subendocardial infarcts
whereas SPECT only identiﬁed 28%. The relative
lack of spatial resolution with SPECT can poten-
tially lead to erroneous conclusions with respect to
viability. Thus, in dysfunctional segments, trans-
mural LGE of 9%, 33%, and 80%, respectively,
corresponds to segments that by combined 99Tc
SPECT/18F-FDG PET (and accepted cut-off values)
are classiﬁed as normal, mismatched (hibernating),
and matched (ﬁbrotic).w22 The classiﬁcation of
‘hibernating’ versus ‘ﬁbrotic’ myocardium by
combined 99Tc SPECT/18F-FDG PET may have
more to do with the extent of transmurality of scar
and appropriateness of chosen cut-off values for
ﬂow (by SPECT) and glucose metabolism (by PET).
BIOMARKERS OF MYOCARDIAL FIBROSIS
In comparison with cardiac imaging, serum
biomarkers of myocardial ﬁbrosis have yet to
achieve general acceptance in clinical practice. This
may relate to the semi-quantitative nature of
measurement techniques, and to inferior speciﬁcity
in a general population, in whom collagen turnover
may be increased due to comorbid conditions.
Nonetheless, serum biomarkers of myocardial
ﬁbrosis are conceptually appealing as they allow
measurement of diffuse ﬁbrosis, the quantiﬁcation
of which remains elusive using current imaging
techniques.
Martos et al found higher concentrations of
serum carboxy-terminal telopeptide of procollagen
type I, amino-terminal propeptide of procollagen
type III, MMP-1, -2, and -9, and TIMP-1 in patients
with diastolic heart failure compared with those
without.20 Serum TIMP-1 concentration has been
associated with echocardiographic indices of
diastolic dysfunction in hypertensive patients.w23
This study demonstrated that serum MMP-2
concentration was the most sensitive and speciﬁc
biomarker of heart failure with preserved ejection
fraction, superior to B-type natriuretic peptide
(BNP).w24 Based on this ﬁnding, the authors
propose an adjunctive role for MMP-2 in the diag-
nosis of this condition, although this is yet to gain
widespread clinical acceptance.
In a cross-sectional study of 1069 subjects from
the Framingham Heart Study, serum TIMP-1
concentration was positively related to LV mass,
end-systolic diameter, and left atrial diameter after
adjustment for age, sex and height.w25 Although
adjustment for further clinical covariates attenu-
ated the strength of association between TIMP-1
concentration and echocardiographic measures, the
authors concluded that this evidence supports the
hypothesis that cardiovascular risk factors promote
LV remodelling by inﬂuencing turnover of the
extracellular matrix.
In a study by Yan et al of systolic heart failure
patients, serum MMP-9 concentration was
demonstrated to have a positive linear relationship
with LV end-systolic volume and a negative asso-
ciation with LVEF.w26 Over 43 weeks follow-up,
there was a negative relationship between change
in serumMMP-9 concentration and change in LVEF.
In contrast, Vorovich et al have recently shown that
serum MMP-9 concentration is a poor marker of LV
remodelling and clinical outcome compared with
BNP.21
At the present time, although associations
between serum ﬁbrosis biomarker concentration and
indices of myocardial disease have been demon-
strated, the clinical role of serological testing remains
to be deﬁned. Moreover, the robustness of these
assays outside of research laboratories is unknown.
FUTURE DIRECTIONS
Novel imaging techniques
There is preliminary research to suggest a potential
role for molecular imaging in ﬁbrosis detection and
quantiﬁcation. Collagen targeting molecules have
Figure 8 (A) Mid ventricular short axis view of a gadolinium delayed enhanced cardiac
magnetic resonance image of a patient with hypertrophic cardiomyopathy. Note patchy
hyperenhancement located at hypertrophied interventricular septum at junctions of
septum and right ventricular free walls (arrows). (B) Anatomic tissue fraction image of
same patient derived by positron emission tomography. Reproduced with permission
from Knaapen et al.w20
Non-invasive evaluation of myocardial fibrosis: key points
< Myocardial fibrosis develops in response to a cardiac insult, and may have
deleterious long term effects on cardiac function and remodelling.
< Collagen deposition in the myocardium is the result of the interplay of various
enzymes including matrix metalloproteinases (MMPs) and tissue inhibitors of
matrix metalloproteinase (TIMPs).
< Cardiac magnetic resonance (CMR) imaging using the late gadolinium
technique can demonstrate scar tissue in ischaemic cardiomyopathy, and can
yield prognostic information.
< Approximately one third of cases of established non-ischaemic dilated
cardiomyopathy will exhibit myocardial fibrosis by the late gadolinium CMR
technique; when present, this is associated with adverse prognosis.
< Late gadolinium enhancement CMR can also demonstrate myocardial fibrosis
in other cardiac conditions, such as hypertrophic cardiomyopathy.
< Strain and backscatter echocardiographic techniques have an emerging role
in the evaluation of focal and diffuse myocardial fibrosis.
< Nuclear imaging techniques are well established for the detection of large
regions of scar tissue; however, their limited spatial resolution prohibits
detection of small regions or diffuse fibrosis.
< Serum biomarkers are yet to gain widespread acceptance in the clinical
evaluation of myocardial fibrosis.
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been appended to Gd-DTPA to image animal
models of myocardial infarction.w27 Such tech-
niques may increase the speciﬁcity for the identiﬁ-
cation of ﬁbrosis and help its distinction from
myocardial oedema.
Diffusion tensor magnetic resonance images
microstructural organisation by use of the property
that the main orientation of microstructures
parallels the main diffusivity of water molecules,
causing signal attenuation in the presence of
a magnetic ﬁeld. Diffusion tensor CMR has been
used post-myocardial infarction to demonstrate
altered ﬁbre architecture that correlates with
infarct size using the LGE technique.w28
Evaluation of response to treatment
A number of therapeutic agents have been associ-
ated with a reduction in myocardial ﬁbrosis. The
measurement of ﬁbrosis burden may therefore be
used as a surrogate end point to guide the ongoing
development of treatments for chronic cardiac
disease. Given the prognostic implications of the
presence and extent of myocardial ﬁbrosis, moni-
toring response to treatment may allow individu-
alisation of therapy, although this remains to be of
proven value in clinical trials.
CONCLUSION
The formation and degradation of myocardial
collagen is a dynamic process. Although net
collagen deposition may serve an as yet poorly
deﬁned physiological purpose, its excess in the
longer term appears to be detrimental to myocar-
dial mechanical function and provides substrate for
cardiac arrhythmia. Hence the detection and
quantiﬁcation of myocardial ﬁbrosis has become
a key focus of recent research. Focal scar, as may be
seen following myocardial infarction, can be
visualised with high spatial resolution using the
LGE-CMR technique, and can be inferred through
its functional consequences in terms of echocar-
diographic measures of LV strain or PET metabolic
imaging. In contrast, diffuse myocardial ﬁbrosis
remains difﬁcult to identify using currently avail-
able imaging modalities, although T1 mapping by
CMR holds promise. There is preliminary evidence
to support the ability of serum markers of collagen
turnover to identify myocardial ﬁbrosis. The utility
and clinical beneﬁt of these assays in ‘real world’
practice remains to be demonstrated.
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